UK’s Issues Final Guidance Backing Eli Lilly and Company’s Alimta

LONDON, Jan 23 (Reuters) - Britain's healthcare cost-effectiveness watchdog, NICE, gave final clearance on Wednesday for doctors to use Eli Lilly and Co's (LLY.N: Quote, Profile, Research) Alimta to treat asbestos-related cancer for certain patients.
MORE ON THIS TOPIC